Exploring the two-gene ratio in breast cancer—independent roles for HOXB13 and IL17BR in prediction of clinical outcome
The two-gene expression ratio HOXB13:IL17BR has been proposed to predict the outcome of tamoxifen-treated breast cancer patients. We intended to examine whether this ratio can predict the benefit of 5 years vs. 2 years of tamoxifen treatment of postmenopausal patients. A further objective was to investigate any prognostic effects of the ratio in systematically untreated premenopausal patients. Based on the current knowledge of HOXB13 and IL17BR, we hypothesized that these genes may have individual prognostic or predictive power.
Patients and methods
Expression of HOXB13 and IL17BR were quantified by real-time PCR in tumors from 264 randomized postmenopausal patients and 93 systemically untreated premenopausal patients.
A high HOXB13:IL17BR ratio was associated with aggressive tumor characteristics, as were low levels of IL17BR alone. The ratio and HOXB13 alone predicted recurrence-free survival after endocrine treatment, with a benefit of prolonged treatment in estrogen receptor-positive patients correlated to a low ratio (recurrence rate ratio: RR = 0.39; P = 0.030), or low expression of HOXB13 (RR = 0.37; P = 0.015). No difference in recurrence-free survival was seen for the high ratio or high HOXB13 subgroups. The predictive value of HOXB13 and HOXB13:IL17BR was significant in multivariate analysis. In the systemically untreated cohort, only IL17BR showed independent prognostic significance.
We conclude that the ratio or HOXB13 alone can predict the benefit of endocrine therapy, with a high ratio or a high expression rendering patients less likely to respond. We have also shown that IL17BR might be an independent prognostic factor in breast cancer.
We are indebted to participating members of the South and Southeast Sweden Breast Cancer Groups for providing us with breast cancer samples and to Gunilla Chebil and Sten Thorstenson for re-evaluation of histological grade. This study was supported by funds from the Swedish Cancer Society, the Gunnar Arvid and Elisabeth Nilsson Foundation, the Mrs Berta Kamprad Foundation, the Swedish Research Council and the University Hospital of Lund Research Foundation.
- 26.Rodriguez BAT, Jin VX, Cheng AS, et al (2006) HOXB13 is an estrogen receptor responsive gene preferentially methylated in ER-positive breast cancer. In: Proceedings of the 97th annual meeting, AACR, Washington, USA, 1–5 April 2006Google Scholar